InspireMD Announces Inventory Exchange Listing Transfer to

TEL AVIV, Israel, May perhaps 10, 2021 (World NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Avoidance Technique (EPS) for the prevention of stroke triggered by the cure of Carotid Artery Condition (CAD), these days declared the Company’s shares have been approved for listing on The Nasdaq Funds Marketplace (“Nasdaq”). Trading is anticipated to start out on May 21, 2021, underneath the image NSPR on the Nasdaq.  

InspireMD CEO Marvin Slosman commented, “We consider that relocating to the Nasdaq Cash Market place is a strategically significant adjust that places us in the firm of our friends and lets us greater accessibility to a broader established of traders, therefore enabling us to establish our elementary base of investors. InspireMD is a more powerful business these days than ever before, and I am happy of the extraordinary attempts of our growing workforce in creating an interesting potential for our corporation. We are very pleased to now be a element of the Nasdaq trade and benefit our new romance.”

About InspireMD, Inc.

InspireMD seeks to make use of its proprietary MicroNet® technological innovation to make its merchandise the marketplace common for carotid stenting by offering fantastic acute results and sturdy, stroke-free of charge, extended-expression outcomes.

As of May well 21, 2021, InspireMD’s common stock will be quoted on the Nasdaq beneath the ticker image NSPR.

Ahead-seeking Statements

This press launch has “forward-looking statements.” This sort of statements may be preceded by the terms “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or identical text. Ahead-hunting statements are not ensures of long term general performance, are primarily based on sure assumptions and are subject matter to several regarded and unidentified threats and uncertainties, lots of of which are outside of the Company’s handle, and can not be predicted or quantified and as a result, real outcomes may perhaps vary materially from people expressed or implied by this kind of forward-seeking statements. These types of pitfalls and uncertainties contain, without having limitation, hazards and uncertainties associated with (i) current market acceptance of our existing and new goods, (ii) destructive scientific demo benefits or prolonged product delays in crucial markets, (iii) an incapability to protected regulatory approvals for the sale of our solutions, (iv) rigorous competition in the clinical unit market from substantially bigger, multinational companies, (v) product or service legal responsibility claims, (vi) merchandise malfunctions, (vii) our minimal producing abilities and reliance on subcontractors for guidance, (viii) insufficient or inadequate reimbursement by governmental and other 3rd bash payers for our goods, (ix) our attempts to properly acquire and keep mental residence defense covering our solutions, which might not be thriving, (x) legislative or regulatory reform of the healthcare method in both equally the U.S. and foreign jurisdictions, (xi) our reliance on one suppliers for sure item components, (xii) the reality that we will have to have to elevate added money to meet our organization demands in the upcoming and that this kind of cash elevating may be high-priced, dilutive or challenging to get and (xiii) the truth that we conduct company in several overseas jurisdictions, exposing us to foreign currency trade fee fluctuations, logistical and communications difficulties, burdens and charges of compliance with international regulations and political and financial instability in each and every jurisdiction. Far more detailed facts about the Company and the threat aspects that may possibly have an impact on the realization of forward-wanting statements is set forth in the Company’s filings with the Securities and Trade Commission (SEC), which include the Company’s Annual Report on Variety 10-K and its Quarterly Reviews on Kind 10-Q. Buyers and safety holders are urged to browse these documents no cost of cost on the SEC’s world-wide-web web page at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its ahead-wanting statements as a end result of new facts, long term gatherings or or else.

Trader Contacts:

Craig Shore
Main Financial Officer
InspireMD, Inc.
888-776-6804
[email protected] 

Core IR
[email protected]